Revenue → Gross Profit: $9.1BGross Profit → Operating cost: $7.7BCardiometabolic health → Revenue: $7.4BMounjaro → Cardiometabolic health: $3.1BOperating cost → Acquired IPR&D: $2.8BOperating cost → R&D: $2.7BOncology → Revenue: $2.2BRevenue → Cost of Revenue: $2.2BOperating cost → Marketing, S&A: $2.1BGross Profit → Operating profit: $1.5BVerzenio → Oncology: $1.4BTrulicity → Cardiometabolic health: $1.3BZepbound → Cardiometabolic health: $1.3BImmunology → Revenue: $1.2BOperating profit → Net Profit: $0.9BTaltz → Immunology: $0.9BJardiance → Cardiometabolic health: $0.7BOperating profit → Taxes: $0.6BHumalog → Cardiometabolic health: $0.5BNeuroscience → Revenue: $0.4BOther oncology → Oncology: $0.3BOther → Revenue: $0.3BOlumiant → Immunology: $0.3BCyramza → Oncology: $0.2BHumulin → Cardiometabolic health: $0.2BEmgality → Neuroscience: $0.2BBasaglar → Cardiometabolic health: $0.2BErbitux → Oncology: $0.2BTyvyt → Oncology: $0.2BOther diabetes → Cardiometabolic health: $0.1BForteo → Other: $0.1BOther neuroscience → Neuroscience: $0.1BCialis → Other: $0.1BOperating cost → Restructuring & other: $0.1BOther income → Net Profit: $0.1BOther immunology → Immunology: $0.1BOthers → Other: $0.1BZyprexa → Neuroscience: $0.0BBaqsimi → Cardiometabolic health: $0.0BAcquired IPR&D$2.8B-5% Y/YBaqsimi$0.0BBasaglar$0.2BCardiometabolic health$7.4B57% Y/YCialis$0.1BCost of Revenue$2.2B17% Y/YCyramza$0.2BEmgality$0.2BErbitux$0.2BForteo$0.1BGross Profit$9.3B1% Y/YHumalog$0.5BHumulin$0.2BImmunology$1.2B20% Y/YJardiance$0.7BMarketing, S&A$2.1B16% Y/YMounjaro$3.1BNet Profit$1.0BNeuroscience$0.4B-80% Y/YOlumiant$0.3BOncology$2.2B28% Y/YOperating cost$7.7B2% Y/YOperating profit$1.5B215% Y/YOther$0.3B-5% Y/YOther diabetes$0.1BOther immunology$0.1BOther income$0.1BOther neuroscience$0.1BOther oncology$0.3BOthers$0.1BR&D$2.7B13% Y/YRestructuring & other$0.1B-81% Y/YRevenue$11.4B4% Y/YTaltz$0.9BTaxes$0.6B28% Y/YTrulicity$1.3BTyvyt$0.2BVerzenio$1.4BZepbound$1.3BZyprexa$0.0BEli Lilly Q3 FY24 Income Statementcreated with SankeyArt.com
2024
Q1 Q2 Q3